Browsing by Author "Tait, Sabrina"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- A critical review to identify data gaps and improve risk assessment of bisphenol A alternatives for human healthPublication . Mhaouty-Kodja, Sakina; Zalko, Daniel; Tait, Sabrina; Testai, Emanuela; Viguié, Catherine; Corsini, Emanuela; Grova, Nathalie; Buratti, Franca Maria; Cabaton, Nicolas J.; Coppola, Lucia; De la Vieja, Antonio; Dusinska, Maria; El Yamani, Naouale; Galbiati, Valentina; Iglesias-Hernández, Patricia; Kohl, Yvonne; Maddalon, Ambra; Marcon, Francesca; Naulé, Lydie; Rundén-Pran, Elise; Salani, Francesca; Santori, Nicoletta; Torres-Ruiz, Mónica; Turner, Jonathan D.; Adamovsky, Ondrej; Aiello-Holden, Kiara; Dirven, Hubert; Louro, Henriqueta; Silva, Maria JoãoBisphenol A (BPA), a synthetic chemical widely used in the production of polycarbonate plastic and epoxy resins, has been associated with a variety of adverse effects in humans including metabolic, immunological, reproductive, and neurodevelopmental effects, raising concern about its health impact. In the EU, it has been classified as toxic to reproduction and as an endocrine disruptor and was thus included in the candidate list of substances of very high concern (SVHC). On this basis, its use has been banned or restricted in some products. As a consequence, industries turned to bisphenol alternatives, such as bisphenol S (BPS) and bisphenol F (BPF), which are now found in various consumer products, as well as in human matrices at a global scale. However, due to their toxicity, these two bisphenols are in the process of being regulated. Other BPA alternatives, whose potential toxicity remains largely unknown due to a knowledge gap, have also started to be used in manufacturing processes. The gradual restriction of the use of BPA underscores the importance of understanding the potential risks associated with its alternatives to avoid regrettable substitutions. This review aims to summarize the current knowledge on the potential hazards related to BPA alternatives prioritized by European Regulatory Agencies based on their regulatory relevance and selected to be studied under the European Partnership for the Assessment of Risks from Chemicals (PARC): BPE, BPAP, BPP, BPZ, BPS-MAE, and TCBPA. The focus is on data related to toxicokinetic, endocrine disruption, immunotoxicity, developmental neurotoxicity, and genotoxicity/carcinogenicity, which were considered the most relevant endpoints to assess the hazard related to those substances. The goal here is to identify the data gaps in BPA alternatives toxicology and hence formulate the future directions that will be taken in the frame of the PARC project, which seeks also to enhance chemical risk assessment methodologies using new approach methodologies (NAMs).
- Hazard assessment of bisphenol A alternatives to close data gaps of concern for human health and improve their risk assessmentPublication . Aiello Holden, Kiara; Tait, Sabrina; Viguié, Catherine; Mhaouty-Kodja, Sakina; Corsini, Emanuela; Silva, Maria João; Zalko, Daniel; Testai, Emanuela; Louro, Henriqueta; Dirven, HubertWHY? With the upcoming restrictions on BPA, BPA alternatives’ tonnages and frequencies of use are expected to severely increase in the coming years. Therefore, this project aims to fill the identified data gaps, providing a complete data set for at least four relevant BPA alternatives identified in an ad hoc Workshop together with ECHA and EFSA. We will fill the knowledge gaps on human health on five toxicological endpoints and by the identification of molecular biomarkers we will contribute to develop methods to rapidly predict the possible effects of BPA alternatives.
- Hazard characterization of the mycotoxins enniatins and beauvericin to identify data gaps and improve risk assessment for human healthPublication . Behr, Anne-Cathrin; Fæste, Christiane Kruse; Azqueta, Amaya; Tavares, Ana M.; Spyropoulou, Anastasia; Solhaug, Anita; Olsen, Ann-Karin; Vettorazzi, Ariane; Mertens, Birgit; Zegura, Bojana; Streel, Camille; Ndiaye, Dieynaba; Spilioti, Eliana; Dubreil, Estelle; Buratti, Franca Maria; Crudo, Francesco; Eriksen, Gunnar Sundstøl; Snapkow, Igor; Teixeira, João Paulo; Rasinger, Josef D.; Sanders, Julie; Machera, Kyriaki; Ivanova, Lada; Gaté, Laurent; Le Hegarat, Ludovic; Novak, Matjaz; Smith, Nicola M.; Tait, Sabrina; Fraga, Sónia; Hager, Sonja; Marko, Doris; Braeuning, Albert; Louro, Henriqueta; Silva, Maria João; Dirven, Hubert; Dietrich, JessicaEnniatins (ENNs) and beauvericin (BEA) are cyclic hexadepsipeptide fungal metabolites which have demonstrated antibiotic, antimycotic, and insecticidal activities. The substantial toxic potentials of these mycotoxins are associated with their ionophoric molecular properties and relatively high lipophilicities. ENNs occur extensively in grain and grain-derived products and are considered a food safety issue by the European Food Safety Authority (EFSA). The tolerable daily intake and maximum levels for ENNs in humans and animals remain unestablished due to key toxicological and toxicokinetic data gaps, preventing full risk assessment. Aiming to find critical data gaps impeding hazard characterization and risk evaluation, this review presents a comprehensive summary of the existing information from in vitro and in vivo studies on toxicokinetic characteristics and cytotoxic, genotoxic, immunotoxic, endocrine, reproductive and developmental effects of the most prevalent ENN analogues (ENN A, A1, B, B1) and BEA. The missing information identified showed that additional studies on ENNs and BEA have to be performed before sufficient data for an in-depth hazard characterisation of these mycotoxins become available.